Defining drug action at
single cell resolution.


Allcyte is a biotech start-up company focused on functional drug testing in primary human material. With our Pharmacoscopy high-content imaging platform, our mission is to bring the next generation of personalized medicine to cancer patients and treating physicians, and support pharmaceutical companies to focus their drug development efforts on the right molecules in the right indications.

We enable research through the image-based quantification of single-cell phenotypes - all performed directly in primary patient material with minimal amounts of manipulation and requiring minimal amounts of sample. We integrate these data using cutting edge methods of statistics and machine learning to generate actionable insights for our customers. Our mission is to help you make the best possible biomedical decisions.

Innovative tech

Pharmacoscopy technology breaks the dogma that high-content and high-throughput imaging can only be performed on adherent cell lines. This opens a whole new method of measuring drug action at the single-cell and sub-cellular level over hundreds of parameters, thousands of patients and millions of cells.

Big data

Per patient we routinely record more than 5 billion data points. This forms a solid basis for the extraction of individualised, clinically translatable information. Over time, we will accumulate drug response data from thousands of patients - creating a unique and powerful dataset for the development of even better diagnostics, drug repurposing and new target discovery.

Machine learning

We believe that an image of a single cell contains an unlimited amount of data, but just collecting this data is useless. Using custom designed algorithms and expert interpretation, we can make powerful use of the data we collect. Not only by interpreting it in meaningful ways but also by visualizing it properly, making the data all the more insightful.

Visionary science

Allcyte's rsearch team is made up of visionary scientists from diverse backgrounds who have excelled in their respective fields, and have united under a common goal: To disrupt functional drug testing through "big data" science. This interdisciplinary approach enables us to tackle complex translational problems.


is a highly robust and efficient assay to determine drug effects ex vivo. It analyses drug action at single cell resolution, working with primary patient samples, simulating as close to possible in vivo conditions. Pharmacoscopy can provide a pre-view of how drugs will likely function in real patients enabling physicians and our pharmaceutical partners to make the best possible decision when prioritizing treatments and research.

> 150 Bn

cells screened

> 100 TB

of images analyzed per year

> 350

data points per cell analyzed


Pharmacoscopy supported clinical studies

what makes it great

Pharmacoscopy is highly adaptable to clinical needs.


We understand access to primary patient samples is limited. For this reason, we designed Pharmacoscopy to have minimal sample need. Very often, left-over samples from routine diagnostic biopsies are sufficient. One 9 mL tube of blood or bone marrow can allow us to test up to 1000 different experimental conditions. This is achieved through analyzing and interrogating each and every individual cell within a primary sample in our microscopy images. We think there is no sense in wasting precious primary cells or material.


Using the latest in screening technology, and our own software and analysis algorithms, we can detect very early phenotypes requiring only short incubation periods, no outgrowth of clonal cell populations, and no sample manipulation. Thus enabling a feedback loop of data either to our medical partners or our research partners efficiently and with the accuracy that translational medicine mandates.


Pharmacoscopy allows us to study cell-autonomous phenotypes and gain a preview of how these cells will likely respond to anticancer drugs in the patient. But it does not end there: For the first time, we can also interrogate the interplay of different cell types in complex mixtures with high resolution. By measuring cell-cell interactions, for example, we can quantify immunomodulatory drug phenotypes such as the formation of immunological synapses between cancer and effector cells to study the power of our immune system to fight cancer. Integrating data over large number of patients we can extract useful patterns including: Which drugs could work in which combinations? Is there potential for new off-label uses or repurposing?


Pharmacoscopy directly measures drug response through the most immediate way of analyzing a cell's function: By looking at it. With single cell resolution. This stands in contrast to techniques where drug response is inferred indirectly from proxy parameters. This direct measurement principle makes results from Pharmacoscopy highly translatable. We further work to limit any manipulation to the primary material we use, there is no cell selection, clonal outgrowth, or long incubation times necessary to make the ex vivo results as relevant for the in vivo situation as possible.

our offer

to Patients

Every patient and every cancer responds differently to anticancer therapy. Our mission is to provide treating oncologists the tools to make the best possible treatment choice for patients to reduce side-effects from potentially ineffective therapy and improve outcome.

to Pharmaceutical Partners

Cell lines do not fully recapitulate the in vivo milieu for individual cells, and many drug candidates fall short of expectations generated by results in preclinical cell line models when reaching human trials. That's why we set out to bridge the translational gap. By testing your anticancer and immune-oncology compounds in real patient samples, we can help understand how drugs will likely perform in real patients or which indication or patient groups to focus on. By comparing ex vivo drug response patterns to sequencing data, we can help you identify biomarker candidates for patient selection even before entering the first clinical study.

to Treating oncologists

We closely work with oncologists and understand that treating cancer patients is extremely challenging. It requires careful integration of clinical guidelines, latest scientific research, diagnostic data and the individual situation of a patient. Our mission is to provide you with high performance tools that generate insight into the likely drug response of a patient that go beyond existing risk classification and genetic prediction systems to help you make the best possible treatment decisions.

We are in the process of developing fully certified in vitro diagnostic tests for the personalized treatment of cancer patients. We aim to bring first tests to market by 2020 in the EU. Already now, however, we invite you to join our groundbreaking research effort and can provide you access to our Pharmacoscopy screening platform for research use only. Please contact us for details.


Dr. Nikolaus Krall, co-founder and CEO
Dr. Gregory Vladimer, co-founder and CSO
Dr. Christina Taubert, scientist/project leader
Dr. Bojan Vilagos, scientist/project leader
Florian Rohrer, MSc, Data Scientist and Bioinformatician
Dr. Noemi Meszaros, scientist
Juan Andrés Munévar Villamizar, BS, software engineer
Isabella Alt, MSc, research associate
Sophie Asamer, MA BA, office manager
Dr. Robert Sehlke, bioinformatician
Elisabeth Fuchs, MSc, Research Associate
Mag. Marie Le Bras, Quality Manager
Dr. Valentin Aranha, Computational Scientist
Diogo Tomaz, MSc, Research Associate
Dr. Irene Gutierrez Perez, Research Scientist
Claudia Baumgärtler, MA, rer nat, Clinical Project Manager
Prof. Berend Snijder, co-founder
Prof. Giulio Superti-Furga, co-founder



  • June 2020:
    Allcyte and Fidelis launch strategic partnership to increase the success rate of translational oncology through functional drug testing in primary human tissues at scale

  • June 2020:
    Prof. Dr. Giulio Superti-Furga, Scientific Director of CeMM and Allcyte scientific co-founder delivered a virtual plenary session address at the European Hematology Association 25th annual meteting - with updates to the EXALT trial.

  • March 2019:
    Allcyte will be attending, and speaking at, AACR and the FPM2019 meeting in Atlanta, Georgia.

  • 11 October 2018:
    Gregory Vladimer, CSO, is on stage at Google Next London 2018 to discuss "tech for good", and how Allcyte uses a expandable cloud-based computational cluster to enable big data precision cancer medicine using single cell phenotypic screening.

  • 17 June 2018:
    CSO, Dr. Gregory Vladimer presents on uncovering ibrutinib combinations by intagrating pharmacoscopy screening and ATAC-seq, in collaboration with CeMM and the Medical University of Vienna

  • 1 February 2018:
    Emerging Company Profile in Biocentury Innovations highlights Allcytes' Pharmacoscopy technology for immunotherapy discovery.

  • 14 January 2018:
    Allcyte partners with Google Cloud Platform to enable ever expanding computational need.

  • 4 December 2017:
    CSO Dr. Gregory Vladimer presents on uncovering ibrutinib combinations by intagrating pharmacoscopy screening and ATAC-seq, in collaboration with CeMM and the Medical University of Vienna
  • 15 November 2017:
    Allcyte co-founders together with CeMM and the Medical University of Vienna publish interim analysis of precision-medicine study prioritzing drugs for late-stage hematological cancers using single-cell image based screening method, Pharmacoscopy.

  • 4 September 2017:
    Allcyte collaborates with Boehringer Ingelheim to advance preclinical oncology drug discovery by using novel drug response profiling technology.

  • 24 April 2017:
    Allcyte co-founders publish study quantifying the immunomodulatory potential of drugs and identify a potential new cancer target.

  • 11 August 2017:
    Allcyte Scientific Co-Founder, and CeMM Scientific Director, Prof. Dr. Giulio Superti-Furga featured on ERC CORDIS.